Regenxbio, a clinical-stage biotech that offers gene therapies based on its proprietary NAV Technology Platform, has teamed up with Fujifilm Diosynth Biotechnologies for the manufacture of Regenxbio’s lead product candidates, including RGX-314 and RGX-501, which will support late-stage clinical development and early commercialization. This partnership builds on the foundation of Regenxbio’s internal manufacturing and process development capabilities. “We are excited to enter into this partner...